GlaxoSmithKline (GSK) has a broad platform covering the three key areas of pharmaceuticals, vaccines and consumer healthcare. It also is one of the few healthcare companies that has treatments for the World Health Organization’s priority diseases, which include HIV/AIDS, malaria and tuberculosis.
Over the years, GSK has been aggressive with acquisitions, though in more recent years the company has shifted to unloading non-core businesses like thrombosis brands Arixtra and Fraxiparine.
The company continues to invest heavily in R&D — which will be critical for building a pipeline that deals with patent expiration of existing drugs. In the past quarter, GSK got regulatory approval for three drugs in the U.S.
GlaxoSmithKline also has an advantage in global distribution, which has enabled GSK to strike bottom-line-boosting agreements with Amgen (AMGN) and others sell their drugs, providing a nice boost to the bottom line.